# A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03496623** · PHASE3 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 188 (actual)

## Conditions studied

- Pulmonary Hypertension
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Inhaled treprostinil solution
- **DRUG:** Placebo solution

## Key facts

- **NCT ID:** NCT03496623
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-08
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 188 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03496623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03496623, "A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03496623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*